PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA- Cancer J Clin 68 394-424

[3] Siegel RL(2019)Colorectal cancer Lancet 394 1467-1480

[4] Laversanne M(2020)Treatment strategies for colorectal cancer patients in tumor hospitals under the background of corona virus disease Zhonghua Wei Chang Wai Ke Za Zhi 23 201-208

[5] Soerjomataram I(2020)Colorectal Cancer Immunotherapy: Options and Strategies Front Immunol 11 1624-4147

[6] Jemal A(2019)Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer Cancer 125 4139-156

[7] Bray F(2003)Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 154-1058

[8] Bray F(2015)Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9) Basic Res Cardio 110 4-915

[9] Ferlay J(2020)Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9 Front Physiol 7 1057-1187

[10] Soerjomataram I(2013)Phase III data for PCSK9 inhibitor wows Nat Biotechnol 31 908-5638

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA- Cancer J Clin 68 394-424

[3] Siegel RL(2019)Colorectal cancer Lancet 394 1467-1480

[4] Laversanne M(2020)Treatment strategies for colorectal cancer patients in tumor hospitals under the background of corona virus disease Zhonghua Wei Chang Wai Ke Za Zhi 23 201-208

[5] Soerjomataram I(2020)Colorectal Cancer Immunotherapy: Options and Strategies Front Immunol 11 1624-4147

[6] Jemal A(2019)Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer Cancer 125 4139-156

[7] Bray F(2003)Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 154-1058

[8] Bray F(2015)Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9) Basic Res Cardio 110 4-915

[9] Ferlay J(2020)Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9 Front Physiol 7 1057-1187

[10] Soerjomataram I(2013)Phase III data for PCSK9 inhibitor wows Nat Biotechnol 31 908-5638